The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients
Open accessAbstract
BACKGROUND: Circulating tumor cells (CTCs) are a prognostic marker in metastatic breast cancer, but comparisons with serum tumor markers (CA 15-3, carcinoembryonic antigen and lactate dehydrogenase) variations are needed. PATIENTS AND METHODS: CTCs were counted with CellSearch® at baseline, before cycle 2 (C2) and cycle 3 or 4 (C3/4) in 267 metastatic breast cancer patients on first-line chemotherapy with/without targeted therapy. RESULTS: Baseline CTC detection rate was 65% with ≥1 CTC/7.5 ml threshold and 44% with ≥5 CTC/7.5 ml and was independent of subtypes (luminal, triple negative, human epithelial growth factor receptor 2 (HER2)+). CTCs were associated with tumor markers, bone/liver involvement, tumor burden and performance status. CTC detection ≥1 CTC/7.5 ml was a strong prognostic factor for progression-free survival (PFS), P < 0.0001. Threshold of CTC ≥5 was statistically significant for PFS and overall survival (OS), P = 0.03 on multivariate analysis. Among patients with ≥5 CTC/7.5 ml at baseline, 50% had <5 CTC/7.5 ml at C2. Changes were correlated with both PFS and OS (P < 0.0001). All patients receiving anti-HER2 therapy had <5 CTC/7.5 ml after three cycles of treatment. CONCLUSION: This is the largest prospective series validating the prognostic value of CTC independently from serum tumor marker. Elevated CTCs before C2 are an early predictive marker of poor PFS and OS, which could be used to monitor treatment benefit. CTC decrease under treatment seems stronger with targeted therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Matera, J., Miller, M. C., Reuben, J. M., Doyle, G. V., Allard, W. J., Terstappen, L. W. M. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040766 · Cited by 4,593
Allard, W. J., Matera, J., Miller, M. C., Repollet, M., Connelly, M. C., Rao, C., Tibbe, A. G. J., Uhr, J. W., & Terstappen, L. W. M. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0378 · Cited by 2,542
Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., Somerfield, M. R., Hayes, D. F., & Bast, R. C. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.2364 · Cited by 2,217
Riethdorf, S., Fritsche, H., Müller, V., Rau, T., Schindlbeck, C., Rack, B., Janni, W., Coith, C., Beck, K., Jänicke, F., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1695 · Cited by 1,338
Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer
Cristofanilli, M., Hayes, D. F., Budd, G. T., Ellis, M. J., Stopeck, A., Reuben, J. M., Doyle, G. V., Matera, J., Allard, W. J., Miller, M. C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.140 · Cited by 1,135
Hayes, D. F., Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Miller, M. C., Matera, J., Allard, W. J., Doyle, G. V., & Terstappen, L. W. W. M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2821 · Cited by 1,030
A case of cancer in which cells similar to those in the tumours were seen in the blood after death
Ashworth, T. G. (1869) · Medical Entomology and Zoology · Cited by 842
Circulating Tumor Cells versus Imaging—Predicting Overall Survival in Metastatic Breast Cancer
Budd, G. T., Cristofanilli, M., Ellis, M. J., Stopeck, A., Borden, E., Miller, M. C., Matera, J., Repollet, M., Doyle, G. V., Terstappen, L. W. M. M., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1769 · Cited by 775
Miller, M. C., Doyle, G. V., & Terstappen, L. W. M. M. (2010) · Journal of Oncology · doi:10.1155/2010/617421 · Cited by 750
Tumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor Markers
Hayes, D. F., Bast, R. C., Desch, C. E., Fritsche, H., Kemeny, N. E., Jessup, J. M., Locker, G. Y., Macdonald, J. S., Mennel, R. G., Norton, L., et al. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.20.1456 · Cited by 748
Pierga, J.-Y., Bidard, F.-C., Mathiot, C., Brain, E., Delaloge, S., Giachetti, S., de Cremoux, P., Salmon, R., Vincent-Salomon, A., & Marty, M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0030 · Cited by 369
Self-citationCirculating Tumor Cells: A Useful Predictor of Treatment Efficacy in Metastatic Breast Cancer
Liu, M. C., Shields, P. G., Warren, R. D., Cohen, P., Wilkinson, M., Ottaviano, Y. L., Rao, S. B., Eng-Wong, J., Seillier-Moiseiwitsch, F., Noone, A.-M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6664 · Cited by 319
Molecular mechanisms of metastasis in breast cancer—clinical applications
Mego, M., Mani, S. A., & Cristofanilli, M. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.171 · Cited by 235
Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer
Bidard, F.-C., Mathiot, C., Delaloge, S., Brain, E., Giachetti, S., de Cremoux, P., Marty, M., & Pierga, J.-Y. (2010) · Annals of Oncology · doi:10.1093/annonc/mdp391 · Cited by 232
Self-citationStatistical considerations for enumeration of circulating tumor cells
Tibbe, A. G. J., Miller, M. C., & Terstappen, L. W. M. M. (2007) · Cytometry Part A · doi:10.1002/cyto.a.20369 · Cited by 215
Nolé, F., Munzone, E., Zorzino, L., Minchella, I., Salvatici, M., Botteri, E., Medici, M., Verri, E., Adamoli, L., Rotmensz, N., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm558 · Cited by 159
Bidard, F., Mathiot, C., Degeorges, A., Étienne-Grimaldi, M.-C., Delva, R., Pivot, X. B., Veyret, C., Bergougnoux, L., de Crémoux, P., Milano, G. A., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq052 · Cited by 145
Self-citationGiorgi, U. D., Valero, V., ROHREN, E. M., Dawood, S. S., Ueno, N. T., Miller, M. C., Doyle, G. V., Jackson, S. A., Andreopoulou, E., Handy, B. C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.4423 · Cited by 136
Nakamura, S., Yagata, H., Ohno, S., Yamaguchi, H., Iwata, H., Tsunoda, N., Ito, Y., Tokudome, N., Toi, M., Kuroi, K., et al. (2009) · Breast Cancer · doi:10.1007/s12282-009-0139-3 · Cited by 124
Are circulating tumor cells predictive of overall survival?
Pantel, K., & Riethdorf, S. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.23 · Cited by 60
Cited by
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Dawson, S.-J., Tsui, D. W. Y., Murtaza, M., Biggs, H., Rueda, O. M., Chin, S.-F., Dunning, M. J., Gale, D., Forshew, T., Mahler-Araujo, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213261 · Cited by 2,207
Circulating tumor cells: biology and clinical significance
Lin, D., Shen, L., Luo, M., Zhang, K., Li, J., Yang, Q., Zhu, F., Zhou, D., Zheng, S., Chen, Y., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00817-8 · Cited by 993
Epithelial Plasticity: A Common Theme in Embryonic and Cancer Cells
Nieto, M. A. (2013) · Science · doi:10.1126/science.1234850 · Cited by 967
Bidard, F.-C., Peeters, D. J., Fehm, T., Nolé, F., Gisbert-Criado, R., Mavroudis, D., Grisanti, S., Generali, D., Garcia-Saenz, J. A., Stebbing, J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70069-5 · Cited by 838
Self-citationTumor Heterogeneity in Breast Cancer
Turashvili, G., & Brogi, E. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00227 · Cited by 561
Metadata
- Authors
- Pierga, J.-Y., Hajage, D., Bachelot, T., Delaloge, S., Brain, E., Campone, M., Diéras, V., Rolland, E., Mignot, L., Mathiot, C., & Bidard, F.-C.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2012-03
- Volume
- 23
- Issue
- 3
- Pages
- 618-624
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2125844297
- Cited by
- 281
- References
- 21
- FWCI
- 9.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.